Login to Your Account



Ixchelsis Gets $14M for Premature Ejaculation Drug

By Cormac Sheridan
Staff Writer

Tuesday, August 6, 2013
Ixchelsis Ltd., a start-up with roots in Pfizer Inc.'s UK R&D facility at Sandwich, in Kent, has raised more than $14 million from TVM Life Science Ventures VII fund for development of an oxytocin antagonist, IX-01, for treating premature ejaculation.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription